A slew of biotech companies studying blood disease treatments presented data this past weekend at the annual American Society of Hematology (ASH) meeting – and, as today’s article observes, “Wall Street was quick to reward [certain companies] as early winners.” For a breakdown of some of the biggest biotech winners and losers coming out of ASH, CLICK HERE.